November 5, 2026
Bonus Content: Cigna Reports While CVS Burns. Here Is What Changes.
Editor’s Note: Last year, Larry Benedict’s readers had the chance at a 279% return on cash – roughly 18x the S&P 500. He did it the same way he’s done it for over 40 years: by getting ahead of money on the move. He now believes the largest move he’s tracked is heading straight for your retirement account. He explains below.
Dear Reader,
Sometime soon, an email is going to land in your inbox from whoever runs your 401(k).
It’ll look like every other update they send…
Most people will scroll right past it. Don’t be one of them.
Because that email is your official notice that the “Trillion-Dollar Transfer” has reached your account…
The biggest change to what your 401(k) can own in its history.
Thanks to Executive Order 14330, as much as $1 trillion in retirement money is about to move somewhere it’s never been allowed to go…
Straight into the corner of the market where SpaceX grew 600,000%.
Hedge fund legend Larry Benedict has been tracking this shift for months.
And here’s what he wants you to know: By the time that email hits your inbox, the early money will have already moved.
That’s why he’s revealing the one ticker to own before the change reaches your statement…
The one sitting directly in the path of that $1 trillion.
Click here and Larry will name it – free.
Regards,
Lauren Wingfield
Managing Editor, The Opportunistic Trader
P.S. Larry’s traded ahead of Washington’s retirement rule changes before – the last one handed his readers the chance at 188% gains. This one is far bigger, and the clock is already running.
Cigna Reports While CVS Burns. Here Is What Changes.
Analyst Targets
- Piper Sandler: Overweight, $370 target
- UBS: Buy, $400 target
- Morgan Stanley: Buy, $361 target
- Guggenheim: Buy, $361 target
- RBC Capital: Outperform, $337 target
- Jefferies: Hold, $307 target (downgrade)
- Raymond James: Outperform, $320 target (downgraded from Strong Buy)
The Context
Cigna releases Q3 2026 results this morning before 6:30 a.m. ET, with the management call at 8:30 a.m. The report hits the market in a sharply altered context. Yesterday, CVS Health fell roughly 12% after announcing it would separate into two independent, publicly traded companies by the first half of 2028. One company would include Aetna and CVS Caremark, while the other would include CVS’s retail pharmacy business of approximately 9,000 stores, plus related community healthcare assets such as MinuteClinic and its mail pharmacy operations. The market spent the day processing a simple verdict: years of vertical integration in healthcare did not pay off at scale.
Cigna walks into that moment as the counter-argument. Its own integration of Express Scripts into Evernorth has been, by most financial measures, the more disciplined version of the same bet. Whether this morning’s numbers confirm that view is what today’s trading will price.
Company Profile
Cigna operates through two principal segments. Evernorth Health Services is the larger revenue engine, housing Express Scripts pharmacy benefit management and a specialty and care services platform. Cigna Healthcare covers the employer-insured and international health businesses. The company reported total 2025 revenues of $274.9bn, up 11% year over year, driven primarily by Evernorth growth.
The Numbers
Consensus entering this morning: $7.52 per share on $72.65bn of revenue. Prior-year Q3 EPS was $7.83, so analysts were already modeling a 4% year-over-year decline. That expected drop is not a deterioration story; it reflects the ongoing mix shift away from fully insured medical lives after the Health Care Service Corporation divestiture.
- Evernorth revenue consensus: $64.1bn, up 6.1% year over year
- Cigna Healthcare revenue consensus: $11.65bn, up 6.6% year over year
- Medical Care Ratio (MCR) consensus: 85.1%, up from 84.8% a year ago
- Total medical customers consensus: 18.37 million
- Evernorth pre-tax adjusted income: expected down 4.7% year over year
- Full-year adjusted EPS guidance floor: $30.45, with consensus at $30.51
The MCR is the number that moves managed care stocks. Cigna guided a 2026 range of 83.7% to 84.7%. A print at or above 85% would signal that stop-loss medical cost pressure and the Individual and Family Plans business are running hotter than management anticipated heading into the year.
Why the Stock Is Moving
Cigna gained roughly 3% on November 4, the day CVS collapsed. That is not coincidence. The market reread the competitive map: a pure-play employer insurer and PBM operator, without the retail pharmacy drag, looks more attractive the morning CVS officially concedes the integrated model needs to be undone.
The question today is whether the operational report confirms that relative strength. Evernorth has beaten on new business wins and specialty volume growth consistently. If pharmacy benefit revenue clears $64bn and the MCR stays inside the guided corridor, the CVS comparison becomes even more favorable for Cigna.
Macro Context
Medical cost trend across the managed care sector remains elevated. UnitedHealth has flagged it. CVS’s Aetna has been managing it. Humana’s Medicare Advantage problems dominated headlines for most of 2025. Cigna’s commercial employer book insulates it from Medicare Advantage exposure, but stop-loss costs have risen industry-wide as high-dollar claims in the self-insured employer market compound. That is precisely what drove MCR to 84.8% in Q3 2025. Any further deterioration this quarter would invite questions about whether 2026 guidance is achievable.
Regulatory scrutiny on PBMs has not abated. Cigna’s rebate-free PBM model, now being transitioned across its fully insured plans with a target of covering at least 50% of Evernorth business by the end of 2028, is a direct response to criticism of the legacy model. It differentiates Cigna from Caremark’s position inside CVS, but execution risk is real.
The rebate model shift also lands inside a market where individual coverage costs are already under pressure. ACA marketplace premiums are rising again as enhanced subsidies expire and the risk pool shrinks, a dynamic that shapes the Individual and Family Plans business Cigna is actively managing down.
Forward Scenarios
Bull
Evernorth clears revenue consensus, MCR holds at or below 84.7%, and management maintains the full-year $30.45 EPS floor. Cigna trades to $340-plus as the sector rotates toward pure employer-benefit operators.
Base
Revenue lands near consensus, MCR comes in at 85.0-85.2%, and guidance is maintained with no meaningful revision. CI trades between $295 and $315, absorbing modest medical cost disappointment against Evernorth strength.
Bear
MCR breaches 85.5%, Evernorth profits miss on PBM margin compression, and management trims the full-year EPS floor. The stock retraces toward its $255 52-week low as sector sentiment turns on cost trend.
Technical Overlay
CI entered this report with its 52-week range spanning roughly $255.53 to $316.26. The stock traded near $295 on November 3, the most recent close ahead of this morning’s report, and it was well above its 200-day moving average. Options implied a 5.2% move on earnings. A clean beat with MCR discipline would likely clear the $310 level; a miss on medical costs would test the $275 area, where the stock consolidated through most of August.
Sector rotation is part of the setup here too. Managed care stocks attracted safety-first capital flows when utilization trends showed signs of stabilizing, rewarding operators with disciplined cost ratios.
Bottom Line
CVS just told the market that combining a pharmacy chain, a PBM, and an insurer under one roof is harder than it looks. Cigna has been running essentially the same integrated model, minus the retail stores, for nearly a decade. The question today is not whether Evernorth is a valuable asset. It clearly is. The question is whether Cigna’s medical cost discipline and MCR management justify the gap between the stock’s current multiple and the analyst consensus target near $340 to $370. This morning’s MCR reading is the single number that answers it.
